Cognitive Decline

The plasma biomarker P-tau217 predicted cognitive decline in patients with preclinical Alzheimer’s disease and may complement cerebrospinal fluid and positron emission tomography as a patient-screening tool in clinical trials.

A pill containing antihypertensives and a statin, with or without aspirin, was associated with reduced functional decline, but not reduced cognitive decline, in those aged 65 years and older, researchers reported in JAMA Neurology.

The use of restorative hearing devices for hearing loss was associated with a 19% decrease in risk for long-term cognitive decline, as well as improvement in cognitive test scores in the short term, researchers reported in JAMA Neurology.

Consuming more than 20% of total daily calories from ultra-processed foods was associated with faster decline in cognition and executive function, researchers reported in JAMA Neurology.

Both moderate aerobic exercise and stretching and balance activities protected against cognitive decline in older adults with mild cognitive impairment, according to research at the Clinical Trials on Alzheimer’s Disease annual meeting.

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.

Klotho protein levels in cerebrospinal fluid and plasma were associated with clinical stages of Alzheimer’s disease, cognitive decline, and amyloid and tau burden, independent of KL-VS heterozygosity status, according to research.

According to published results, no significant clinical differences were found in long-term cognitive trajectories of patients who underwent total joint arthroplasty compared with patients without total joint arthroplasty.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.

CHICAGO — Impairments in decision-making may be among the earliest signs of cognitive decline, according to a presenter at the 2022 American Neurological Association annual meeting.